Densitas Announces the Commercial Availability of intelliRisk, a High-Risk Breast Cancer Patient Management Platform

Leader in Operational AI Solutions to Showcase its New Risk Offering at NCBC Annual Meeting in Las Vegas, March 21-23, 2025

HALIFAX, NS, March 20, 2025 – Densitas®, a global leader in artificial intelligence solutions for breast cancer screening, announces the commercial availability of intelliRisk™, its new high-risk breast cancer patient management platform following its successful debut at RSNA 2024. IntelliRisk joins Densitas’ intelliMammo® and intelliMaven™ breast screening solutions as a pivotal advancement in comprehensive, proactive management of high-risk patients, broadening the company’s capabilities in high-risk breast cancer patient management solutions.

IntelliRisk is the latest addition to Densitas’ suite of breast screening solutions, complementing its existing Operational AI tools to provide healthcare systems with a cohesive approach to high risk patient and population health management, and clinical decision-making. 

IntelliRisk equips healthcare providers to efficiently identify, assess, and manage high-risk patients. It incorporates established clinical guidelines and best practices to support informed decision-making across the patient care continuum, from initial screening through long-term follow-up, tailored to individual women. Available as a standalone web application or integrated with EHR systems, intelliRisk delivers personalized screening guidance and patient management workflows. The solution promises to streamline provider workflows and improve patient outcomes in breast cancer care.

IntelliRisk empowers breast health professionals in breast imaging, oncology, genetics, and population health with optimized management of operational and clinical workflows. By enabling lifetime breast cancer risk assessment and high-risk patient management, intelliRisk supports the four pillars of mammography quality service delivery:

• Quality: provides precise, individualized breast cancer risk assessments, ensuring that treatment plans are tailored to each patient’s unique risk profile.
• Efficiency: streamlined clinical and risk factor data integration enables rapid access to comprehensive risk insights, allowing for faster, more coordinated decision-making in patient management.
• Compliance: supports healthcare providers in meeting clinical guidelines by offering a structured approach to identify, monitor, and document high-risk patients, aligning with national standards for cancer care.
• Sustainability: prioritizes proactive management of high-risk patients to optimize resource allocation, and maintain competitive advantage versus other healthcare providers, contributing to sustainable practices that focus on prevention and targeted surveillance over time.

“Since the launch of intelliRisk™, we are gaining strong traction with active deployments and planned implementations of both intelliRisk™ and intelliMammo® together,” said Mo Abdolell, CEO of Densitas. “A comprehensive suite is critical because accurate lifetime breast cancer risk assessment depends on proper mammography positioning. Inadequate positioning compromises breast density assessments so that they are less reliable and reproducible, which in turn similarly impacts risk assessments and downstream care decisions. Integrating intelliMammo® and intelliRisk™ also ensures that providers have a seamless, data-driven workflow that not only increases patient engagement and adherence but also drives better clinical outcomes across the entire breast cancer care continuum.”

Discover how intelliRisk™ can transform your mammography practice at the upcoming Annual Interdisciplinary Breast Center Conference – NCBC. Visit Densitas booth #602. https://densitashealth.com/ncbc-visit-us/

About Densitas

Densitas® delivers scalable Operational AI solutions for breast cancer screening and breast imaging. Our integrated suite improves mammography image quality, streamlines workflows, and drives clinical excellence. At the core is intelliMammo, which ensures continuous quality improvement and FDA MQSA compliance by standardizing mammography positioning – the essential foundation for accurate breast density measurements and risk assessment. Our AI suite supports NAPBC accreditation with precise breast density and breast cancer risk assessments for high-risk breast cancer patient management. For more information, visit www.densitashealth.com.